Top

Canadian Journal of Anesthesia/Journal canadien d'anesthésie

Published in:

01-07-2009 | Reports of Original Investigations

Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery

Authors: Ravi Taneja, FRCA, Gulshan Marwaha, MD, Prabhat Sinha, MD, Mackenzie Quantz, MD, Larry Stitt, MSc, Rouchu Gao, MSc, Seetha Subramanian, DA, Maureen Schaus, ART, Mike Keeney, ART, Ian Chin-Yee, MD, John Murkin, MD

Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie | Issue 7/2009

Abstract

Purpose

Exposure to cardiopulmonary bypass (CPB) is associated with postoperative coagulopathy and hemorrhage. Recent literature indicates that heparin rebound occurs almost universally following cardiac surgery. We conducted this pilot study to evaluate if the presence of residual circulating heparin following cardiac surgery can be diagnosed by elevation of activated partial thromboplastin time (APTT).

Method

After obtaining Research Ethics Board approval, blood samples from 30 patients receiving heparin for CPB were evaluated at the time of intensive care unit admission and 2, 4, and 6 hr thereafter. Activated clotting time, whole blood heparin concentration (Hepcon HMS Plus, Medtronic), anti-Xa levels, and APTT were measured at each time point. Samples with prolonged APTT were subjected to mechanistic studies with heparin adsorption and 1:1 mixing.

Results

Anti-Xa was elevated in 52 of the 120 blood samples (0.08 ± 0.08 U · mL⁻¹, mean ± SD). APTT was elevated in 49 (40.8%) samples with an average of 51.4 ± 31.9 sec. At all time points, the APTT correlated poorly with anti-Xa levels with correlation coefficients ranging from −0.26 to −0.05. Mean APTT was modestly, but not significantly, associated with total dose of protamine with r = 0.34 (CI: −0.03, 0.62). After 1:1 mixing studies, APTT returned to normal in most (82%) samples tested.

Conclusion

Circulating residual heparin is commonly presented following cardiac surgery and does not correlate with APTT. Considering that mixing studies normalize APTT in most samples, elevated APTT following CPB may reflect deficiency of coagulation factors or presence of a coagulation inhibitor such as protamine. Further studies are required to confirm this observation.

Unsworth-White MJ, Herriot A, Valencia O, et al. Resternotomy for bleeding after cardiac operation: a marker for increased morbidity and mortality. Ann Thorac Surg 1995; 59: 664–7.PubMedCrossRef

Sellman M, Intonti MA, Ivert T. Reoperations for bleeding after coronary artery bypass procedures during 25 years. Eur J Cardiothorac Surg 1997; 11: 521–7.PubMedCrossRef

Munoz JJ, Birkmeyer NJ, Dacey LJ, Birkmeyer JD, Charlesworth DC, Johnson ER, et al. Trends in rates of reexploration for hemorrhage after coronary artery bypass surgery. Northern New England Cardiovascular Disease Study Group. Ann Thorac Surg 1999; 68: 1321–5.

Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453–62.PubMedCrossRef

Koch CG, Li L, Van Wagoner DR, Duncan AI, Gillinov AM, Blackstone EH. Red cell transfusion is associated with an increased risk for postoperative atrial fibrillation. Ann Thorac Surg 2006; 82: 1747–56.PubMedCrossRef

Koch CG, Li L, Sessler DI, Figueroa P, Hoeltge GA, Mihaljevic T, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med 2008; 358: 1229–39.PubMedCrossRef

Paparella D, Brister SJ, Buchanan MR. Coagulation disorders of cardiopulmonary bypass: a review. Intensive Care Med 2004; 30: 1873–81.PubMedCrossRef

Shore-Lesserson L, Reich DL, DePerio M. Heparin and protamine titration do not improve haemostasis in cardiac surgical patients. Can J Anaesth 1998; 45: 10–8.PubMedCrossRef

Jobes DR, Aitken GL, Shaffer GW. Increased accuracy and precision of heparin and protamine dosing reduces blood loss and transfusion in patients undergoing primary cardiac operations. J Thorac Cardiovasc Surg 1995; 110: 36–45.PubMedCrossRef

10.

Despotis GJ, Summerfield AL, Joist JH, et al. Comparison of activated coagulation time and whole blood heparin measurements with laboratory plasma anti-Xa heparin concentration in patients having cardiac operations. J Thorac Cardiovasc Surg 1994; 108: 1076–82.PubMed

11.

Martin P, Horkay F, Gupta NK, Gebitekin C, Walker DR. Heparin rebound phenomenon—much ado about nothing? Blood Coagul Fibrinolysis 1992; 3: 187–91.PubMed

12.

Gravlee GP, Rogers AT, Dudas LM, et al. Heparin management protocol for cardiopulmonary bypass influences postoperative heparin rebound but not bleeding. Anesthesiology 1992; 76: 393–401.PubMedCrossRef

13.

Esposito RA, Culliford AT, Colvin SB, Thomas SJ, Lackner H, Spencer FC. Heparin resistance during cardiopulmonary bypass. The role of heparin pretreatment. J Thorac Cardiovasc Surg 1983; 85: 346–53.PubMed

14.

Teoh KH, Young E, Blackall MH, Roberts RS, Hirsh J. Can extra protamine eliminate heparin rebound following cardiopulmonary bypass surgery? J Thorac Cardiovasc Surg 2004; 128: 211–9.PubMedCrossRef

15.

Taneja R, Fernandes P, Marwaha G, Cheng D, Bainbridge D. Perioperative coagulation management and blood conservation in cardiac surgery: a Canadian survey. J Cardiothorac Vasc Anesth 2008; 22: 662–9.PubMedCrossRef

16.

Barstad RM, Stephens RW, Hamers MJ, Sakariassen KS. Protamine sulphate inhibits platelet membrane glycoprotein Ib-von Willebrand factor activity. Thromb Haemost 2000; 83: 334–7.PubMed

17.

Mochizuki T, Olson PJ, Szlam F, Ramsay JG, Levy JH. Protamine reversal of heparin affects platelet aggregation and activated clotting time after cardiopulmonary bypass. Anesth Analg 1998; 87: 781–5.PubMedCrossRef

18.

Nybo M, Madsen JS. Serious anaphylactic reactions due to protamine sulfate: a systematic literature review. Basic Clin Pharmacol Toxicol 2008; 103: 192–6.PubMedCrossRef

19.

Nielsen VG. Protamine enhances fibrinolysis by decreasing clot strength: role of tissue factor-initiated thrombin generation. Ann Thorac Surg 2006; 81: 1720–7.PubMedCrossRef

20.

Palermo LM, Andrews RW, Ellison N. Avoidance of heparin contamination in coagulation studies drawn from indwelling lines. Anesth Analg 1980; 59: 222–4.PubMedCrossRef

21.

Santoro S, Eby C. Laboratory evaluation of hemostatic disease. In: Hoffman R, editor. Hematology-Basic Principles and Practice. 3rd ed. Philadelphia: Churchill Livingstone; 2000. p. 1841–9.

22.

Armitage P, Berry G. Statistical Methods in Research, vol. 2. Oxford: Backwell Scientific Publications; 1987.

23.

Snedecor G, Cochran G. Statistical Methods, vol. 6. Iowa: The Iowa State Press; 1967.

24.

Hirsh J, Warkentin TE, Shaughnessy SG, et al. Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety. Chest 2001; 119: 64S–94S.PubMedCrossRef

25.

Ramsey G, Arvan DA, Stewart S, Blumberg N. Do preoperative laboratory tests predict blood transfusion needs in cardiac operations? J Thorac Cardiovasc Surg 1983; 85: 564–9.PubMed

26.

Nuttall GA, Oliver WC, Beynen FM, Santrach PJ, Strickland RA, Murray MJ. Determination of normal versus abnormal activated partial thromboplastin time and prothrombin time after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1995; 9: 355–61.PubMedCrossRef

27.

Despotis GJ, Filos KS, Zoys TN, Hogue CW Jr, Spitznagel E, Lappas DG. Factors associated with excessive postoperative blood loss and hemostatic transfusion requirements: a multivariate analysis in cardiac surgical patients. Anesth Analg 1996; 82: 13–21.PubMedCrossRef

28.

Nuttall GA, Oliver WC, Ereth MH, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 815–23.PubMedCrossRef

29.

Chavez JJ, Weatherall JS, Strevels SM, Liu F, Snider CC, Carroll RC. Evaluation of a point-of-care coagulation analyzer on patients undergoing cardiopulmonary bypass surgery. J Clin Anesth 2004; 16: 7–10.PubMedCrossRef

30.

Blome M, Isgro F, Kiessling AH, et al. Relationship between factor XIII activity, fibrinogen, haemostasis screening tests and postoperative bleeding in cardiopulmonary bypass surgery. Thromb Haemost 2005; 93: 1101–7.PubMed

31.

Bishop CV, Renwick WE, Hogan C, Haeusler M, Tuckfield A, Tatoulis J. Recombinant activated factor VII: treating postoperative hemorrhage in cardiac surgery. Ann Thorac Surg 2006; 81: 875–9.PubMedCrossRef

32.

Welsby IJ, Jiao K, Ortel TL, et al. The kaolin-activated thrombelastograph predicts bleeding after cardiac surgery. J Cardiothorac Vasc Anesth 2006; 20: 531–5.PubMedCrossRef

33.

Chong SK, Kum SP, Mi JY, Kyoung OK. Effects of intravascular volume therapy using hydroxyethyl starch (130/0.4) on post-operative bleeding and transfusion requirements in children undergoing cardiac surgery: a randomized clinical trial. Acta Anaesthesiol Scand 2006; 50: 108–11.CrossRef

34.

Niranjan G, Asimakopoulos G, Karagounis A, Cockerill G, Thompson M, Chandrasekaran V. Effects of cell saver autologous blood transfusion on blood loss and homologous blood transfusion requirements in patients undergoing cardiac surgery on- versus off-cardiopulmonary bypass: a randomised trial. Eur J Cardiothorac Surg 2006; 30: 271–7.PubMedCrossRef

35.

Mohr R, Martinowitz U, Golan M, Ayala L, Goor DA, Ramot B. Platelet size and mass as an indicator for platelet transfusion after cardiopulmonary bypass. Circulation 1986; 74: III153–8.PubMed

36.

Khuri SF, Wolfe JA, Josa M, et al. Hematologic changes during and after cardiopulmonary bypass and their relationship to the bleeding time and nonsurgical blood loss. J Thorac Cardiovasc Surg 1992; 104: 94–107.PubMed

37.

Essell JH, Martin TJ, Salinas J, Thompson JM, Smith VC. Comparison of thromboelastography to bleeding time and standard coagulation tests in patients after cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 410–5.PubMedCrossRef

38.

Gravlee GP, Arora S, Lavender SW, et al. Predictive value of blood clotting tests in cardiac surgical patients. Ann Thorac Surg 1994; 58: 216–21.PubMedCrossRef

39.

Nuttall GA, Oliver WC Jr, Beynen FM, Dull JJ, Murray MJ, Nichols WL. Intraoperative measurement of activated partial thromboplastin time and prothrombin time by a portable laser photometer in patients following cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1993; 7: 402–9.PubMedCrossRef

40.

Miller BE, Mochizuki T, Levy JH, et al. Predicting and treating coagulopathies after cardiopulmonary bypass in children. Anesth Analg 1997; 85: 1196–202.PubMedCrossRef

41.

Olson JD, Arkin CF, Brandt JT, et al. College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: laboratory monitoring of unfractionated heparin therapy. Arch Pathol Lab Med 1998; 122: 782–98.PubMed

42.

Nelson DE. Current considerations in the use of the APTT in monitoring unfractionated heparin. Clin Lab Sci 1999; 12: 359–64.PubMed

43.

Adcock DM, Kressin DC, Marlar RA. Effect of 32% vs. 38% sodium citrate concentration on routine coagulation testing. Am J Clin Pathol 1997; 107: 105–10.PubMed

44.

Brill-Edwards P, Ginsberg JS, Johnston M, Hirsh J. Establishing a therapeutic range for heparin therapy. Ann Intern Med 1993; 119: 104–9.PubMed

45.

Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays. J Cardiothorac Vasc Anesth 1997; 11: 24–8.PubMedCrossRef

46.

Despotis GJ, Joist JH, Hogue CW Jr, et al. More effective suppression of hemostatic system activation in patients undergoing cardiac surgery by heparin dosing based on heparin blood concentrations rather than ACT. Thromb Haemost 1996; 76: 902–8.PubMed

47.

Bevan DH. Cardiac bypass haemostasis: putting blood through the mill. Br J Haematol 1999; 104: 208–19.PubMedCrossRef

48.

Inagaki M, Goto K, Katayama H, Benson KT, Goto H, Arakawa K. Activated partial thromboplastin time-protamine dose relation in the presence and absence of heparin. J Cardiothorac Anesth 1989; 3: 734–6.PubMedCrossRef

49.

Carr ME Jr, Carr SL. At high heparin concentrations, protamine concentrations which reverse heparin anticoagulant effects are insufficient to reverse heparin anti-platelet effects. Thromb Res 1994; 75: 617–30.PubMedCrossRef

50.

Perkash A. A comparison of the quantitative action of protamine and heparin on blood coagulation. Significance in clinical and laboratory usage. Am J Clin Pathol 1980; 73: 676–81.PubMed

51.

Hardy JF, Belisle S, Robitaille D, Perrault J, Roy M, Gagnon L. Measurement of heparin concentration in whole blood with the Hepcon/HMS device does not agree with laboratory determination of plasma heparin concentration using a chromogenic substrate for activated factor X. J Thorac Cardiovasc Surg 1996; 112: 154–61.PubMedCrossRef

52.

Shore-Lesserson L. Transfusion algorithms: more than just alphabet soup? J Cardiothorac Vasc Anesth 1997; 11: 813–4.PubMedCrossRef

53.

Butterworth J, Lin YA, Prielipp R, Bennett J. James R The pharmacokinetics and cardiovascular effects of a single intravenous dose of protamine in normal volunteers. Anesth Analg 2002; 94: 514–22.PubMedCrossRef

Title: Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery
Authors: Ravi Taneja, FRCA
Gulshan Marwaha, MD
Prabhat Sinha, MD
Mackenzie Quantz, MD
Larry Stitt, MSc
Rouchu Gao, MSc
Seetha Subramanian, DA
Maureen Schaus, ART
Mike Keeney, ART
Ian Chin-Yee, MD
John Murkin, MD
Publication date: 01-07-2009
Publisher: Springer-Verlag
Published in: Canadian Journal of Anesthesia/Journal canadien d'anesthésie / Issue 7/2009
Print ISSN: 0832-610X
Electronic ISSN: 1496-8975
DOI: https://doi.org/10.1007/s12630-009-9098-6

2024 ASCO Annual Meeting

Springer Medicine

Elevated activated partial thromboplastin time does not correlate with heparin rebound following cardiac surgery

Abstract

Purpose

Method

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2009

ICU Recall 3rd Edition

Review article: anatomical considerations for ultrasound guidance for regional anesthesia of the neck and upper limb

Excellent intubating conditions with remifentanil–propofol and either low-dose rocuronium or succinylcholine

Preparation of the Dräger Fabius GS™ workstation for malignant hyperthermia-susceptible patients

How low can you go? Lowest effective dose of neuromuscular blocking agent for tracheal intubation

Canadian contributions to the introduction and use of divinyl ether